COST-EFFECTIVENESS OF DOLUTEGRAVIR, A NEW GENERATION INTEGRASE INHIBITOR, IN HIV-1 TREATMENT EXPERIENCED PATIENTS IN FRANCE

被引：0
|
作者：
Despiegel, N. [1 ]
Marcellin, A. G. [2 ]
Aubin, C. [3 ]
Espinas, C. [1 ]
Laurisse, A. [4 ]
Pialoux, G. [5 ]
机构：
[1] Optum, Nanterre, France
[2] Hop La Pitie Salpetriere, AP HP, Paris, France
[3] GlaxoSmithKline, Marly Le Roi, France
[4] ViiV Healthcare France, Marly Le Roi, France
[5] Hop Tenon, AP HP, F-75970 Paris, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2526
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN85
引用
收藏
页码：A678 / A679
页数：3
相关论文
共 50 条
  • [11] Dolutegravir: A Next-Generation Integrase Inhibitor for Treatment of HIV Infection
    Osterholzer, Danielle A.
    Goldman, Mitchell
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (02) : 265 - 271
  • [12] COST-EFFECTIVENESS ANALYSIS OF DOLUTEGRAVIR FOR HIV PATIENTS IN SLOVENIA
    Hren, R.
    Camejo, Refoios R.
    VALUE IN HEALTH, 2014, 17 (07) : A673 - A673
  • [13] Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection
    Mauskopf, Josephine
    Brogan, Anita J.
    Talbird, Sandra E.
    Martin, Silas
    AIDS, 2012, 26 (03) : 355 - 364
  • [14] Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy
    Hornberger, J
    Green, J
    Wintfeld, N
    Cavassini, M
    Rockstroh, A
    Giuliani, G
    De Carli, C
    Lazzarin, A
    HIV CLINICAL TRIALS, 2005, 6 (02): : 92 - 102
  • [15] Synthesis of Three Key Impurities of Drug Dolutegravir: An Inhibitor of HIV-1 Integrase
    Garrepalli, Sailaja
    Gudipati, Ramesh
    Ravindhranath, Kunta
    Pal, Manojit
    POLYCYCLIC AROMATIC COMPOUNDS, 2023, 43 (04) : 3706 - 3719
  • [16] Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans
    Castellino, Stephen
    Moss, Lee
    Wagner, David
    Borland, Julie
    Song, Ivy
    Chen, Shuguang
    Lou, Yu
    Min, Sherene S.
    Goljer, Igor
    Culp, Amanda
    Piscitelli, Stephen C.
    Savina, Paul M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (08) : 3536 - 3546
  • [17] Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease
    Sax, PE
    Losina, E
    Weinstein, MC
    Paltiel, AD
    Goldie, SJ
    Muccio, TM
    Kimmel, AD
    Zhang, H
    Freedberg, KA
    Walensky, RP
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 39 (01) : 69 - 77
  • [18] Dolutegravir: A New Integrase Strand Transfer Inhibitor for the Treatment of HIV - An Alternative Viewpoint
    Gillette, Michael A.
    Shah, Bhavik M.
    Schafer, Jason J.
    DeSimone, Joseph A., Jr.
    PHARMACOTHERAPY, 2014, 34 (09): : A173 - A174
  • [19] Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States
    Simpson, Kit N.
    Roberts, Graeme
    Hicks, Charles B.
    Finnern, Henrik W.
    HIV CLINICAL TRIALS, 2008, 9 (04): : 225 - 237
  • [20] Bictegravir HIV integrase inhibitor, Treatment of HIV-1 infection
    Cole, P.
    DRUGS OF THE FUTURE, 2017, 42 (09) : 541 - 547
12345